FINWIRES · TerminalLIVE
FINWIRES

Santos Exits Q2 With More Positive Near-Term Outlook After Addressing Key Challenges, Jarden Says

By

Santos (ASX:STO) ended the June quarter with a more positive near-term outlook after resolving several challenges that impacted production and free cash flow, Jarden said in a late Thursday note.

Commissioning issues at the company's Barossa operations in the Timor Sea, which dragged production and sales revenue, appear to be mostly addressed, while the Pikka project in Alaska is on track to hit plateau rates by the end of the current quarter, the equity research firm said.

The company's June quarter production of 23.1 million barrels of oil equivalent came in 1% ahead of Jarden's forecast, but its sales revenue of about $1.35 billion was 5% below Jarden's estimate due to underlifted volumes in Papua New Guinea and a miss in realized liquefied natural gas price.

Santos also downgraded its full-year production outlook by 3.8% at the midpoint to a range of 99 to 105 million barrels of oil equivalent. Jarden said that while it expected the cut, Barossa is now producing at 97% of "planned rates," suggesting a resolution of its performance issues.

The investment firm expects Santos to benefit from its exposure to oil and LNG prices as the Middle East conflict continues to flow into higher commodity prices, although the lag effect means the true benefits won't be seen until the second half of the year.

Jarden maintained an overweight rating on Santos while raising the target price to AU$7.90 from AU$7.65.

The company's shares gained 2% in recent Friday trade.

Related Articles

Asia

Sichuan Biokin Pharmaceutical's ADC Enters Phase Three Trial for Biliary Tract Cancer

Sichuan Biokin Pharmaceutical (SHA:688506) said the first patient for its third-phase randomized controlled clinical trial has been dosed, according to a Friday filing with the Shanghai bourse.The trial is evaluating the company's flagship EGFR×HER3 bispecific antibody drug conjugate (ADC), Lunka Yilong Tuodan/Yizekang, for locally advanced or metastatic biliary tract cancer after platinum chemotherapy failure.Shares of the pharmaceutical company were down 4% in recent trade.

SHA:688506
Asia

Tcm Biotech's Safety Trial for UTI Drug to Continue After Review

Tcm Biotech International (TPE:4169) said an independent review of the interim analysis for its Phase three trial of U101, an oral drug candidate to prevent recurrent urinary tract infections in women, recommended the study continue as planned.The Independent Data Monitoring Committee found the trial's overall safety profile to be sound and recommended continuing patient enrollment, according to a Thursday Taiwan Exchange filing.The company did not disclose efficacy or statistical results, in line with the trial protocol.The trial aims to enroll 348 women, and is assessing U101's ability to prevent recurrent urinary tract infections over a 24-week treatment period.

TPE:4169
Asia

Market Chatter: Indian Billionaire Gautam Adani Considers Entering Airline Business

The group of Gautam Adani is considering launching a new airline, Reuters reported Thursday, citing two sources with direct knowledge of the matter.The report said no final decision has been made, with the group still evaluating the proposal given the challenges of generating profits in the airline industry.The Indian government has privately encouraged several business groups, including Adani, to consider starting an airline as Air India dealt with the aftermath of last year's fatal Ahmedabad crash and IndiGo faced operational disruptions, according to the report.Adani Enterprises (NSE:ADANIENT, BOM:512599), the Indian billionaire's flagship company, did not immediately respond to' request for comment.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

BOM:512599NSE:ADANIENT